MedTrace Logo

Effect of Quetiapine on Sleep Architecture in Bipolar Depression and Major Depressive Disorder

NCT00616889 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 15

Last updated 2015-12-16

No results posted yet for this study

Summary

Clinical practice indicates that Quetiapine has sedating properties, and its sedative effects may play an important role in restoring quality of sleep in patients with various psychiatric conditions who frequently experience sleep disturbances as part of their illness. It is well known that depressive disorders are very frequently associated with significant sleep disturbance. Sleep disruption is a feature of Bipolar Disorder during both Depressed and Manic/Hypomanic episodes. Considering that Seroquel has good antidepressant properties (Calabrese, 2004), the investigators suggest that Seroquel's effect on sleep architecture contributes to its antidepressant properties.

Conditions

Interventions

DRUG

Seroquel

The dosage is flexible from 50-600 mg based on the investigator's clinical judgement and patient tolerance. It may be raised or lowered at will.

Sponsors & Collaborators

  • AstraZeneca

    collaborator INDUSTRY

  • Queen's University

    lead OTHER

Principal Investigators

  • Roumen V Milev, MD · Queen's University

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-05-31
Primary Completion
2009-01-31
Completion
2009-01-31

Countries

  • Canada

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00616889 on ClinicalTrials.gov